Key Highlights
- Second-quarter revenue reached $15.38 billion, reflecting a 5% increase at constant exchange rates
- Core earnings per share jumped 18% to $2.63, surpassing Wall Street’s $2.48 projection
- Cancer treatment division revenue surged 15% at constant currency, compensating for weakness elsewhere
- Company maintains ambitious $80 billion revenue goal for 2030
- Ultomiris late-stage trial fell short of primary endpoint; Wainua study also disappointed earlier in the month
Shares of AstraZeneca advanced approximately 1.6% during Monday’s early session following the pharmaceutical giant’s announcement of second-quarter financial results that exceeded market forecasts.
The company generated $15.38 billion in quarterly revenue, up from $14.46 billion recorded during the corresponding period one year ago. This represents a 5% growth rate when measured at constant exchange rates. Wall Street analysts had projected $15.39 billion, meaning the company nearly matched expectations on revenue.
However, the profit figures delivered a more substantial surprise. Core earnings per share reached $2.63, marking an 18% increase at constant currency and exceeding the Street’s consensus forecast of $2.48. Bottom-line net profit climbed to $2.51 billion compared with $2.45 billion in the prior-year quarter.
The oncology division served as the primary growth driver for the period. Revenue from the company’s cancer treatment portfolio expanded 15% at constant currency, more than offsetting declines seen across cardiovascular, renal and metabolism, and infectious disease business segments.
Clinical Trial Setbacks Draw Attention
AstraZeneca’s recent clinical development track record has come under increased investor scrutiny in recent weeks. Earlier in the month, a late-stage clinical trial evaluating Wainua for treating a cardiac condition failed to achieve its primary endpoint, triggering a selloff in the stock.
Over the weekend, the pharmaceutical company revealed another disappointment. A clinical study testing its rare disease treatment Ultomiris did not achieve its primary objective in patients suffering from a life-threatening complication associated with stem-cell transplantation procedures.
Providing some balance, AstraZeneca simultaneously announced positive results from a late-stage trial in gastric cancer treatment.
Chief Executive Officer Pascal Soriot sought to allay investor concerns. “We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months,” he stated.
Long-Term Revenue Projection Unchanged
Notwithstanding the recent clinical disappointments, AstraZeneca maintained its financial outlook. The pharmaceutical company continues to anticipate 2026 core earnings per share growth in the low double-digit percentage range at constant currency, accompanied by total revenue growth at a mid-to-high single-digit percentage rate.
The ambitious $80 billion annual revenue objective for 2030, initially established in 2024, was reconfirmed. JPMorgan research analysts indicated Monday that they continue to view the company as being on course to achieve that milestone.
AZN shares have increased more than fourfold in value since Soriot assumed leadership 14 years ago. However, the stock has declined approximately 8% year-to-date in 2026, underperforming competitor GSK.
Two additional late-stage clinical trial results expected in the coming months are being monitored closely as investors assess whether the development pipeline can sustain momentum.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
